Elanco Animal Health Incorporated ELAN
At closeNov 6, 2026, 4:19 PM EST
After hours · Nov 6, 4:19 PM ET
- YTD
- +13.74%
- 1 year
- +19.61%
- Market cap
- 12.86B
- Revenue (ttm)
- 5.02B
- Profit margin
- -3.96%
- EPS (ttm)
- -0.41
- Shares out
- 499.62M
- Forward P/E
- 20.22
- YTD return
- +13.74%
- 1-year return
- +19.61%
- Volume
- 11.51M
- Avg volume
- 5.87M
- Open
- 24.07
- Previous close
- 23.68
- Day's range
- 23.97 – 26.26
- 52-week range
- 19.80 – 26.84
- Beta
- 1.72
- Analysts
- Buy
- Price target
- 30.23 (+17.4%)
- Earnings date
- Feb 23, 2027
5D +2.18 (+9.25%)
Key statistics
- Enterprise value
- 15.53B
- PEG ratio
- 4.04
- Price / sales
- 2.56
- Price / book
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.20%
- Free cash flow
- 826.88M
- Total cash
- 530.00M
- Total debt
- 4.23B
- Return on equity
- -2.98%
- Short % of float
- 9.89%
- 50-day average
- 23.11
- 200-day average
- 23.79
Analyst view
Consensus: buy
- Target (low)
- 24.00
- Target (mean)
- 30.23
- Target (high)
- 34.00
- Strong buy4
- Buy9
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.18323.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.18 | — | — | — |
| Nov 6, 2026 | Sep 30, 2026 | 0.2028 | 0.27 | +0.07 | +33.14% |
| Aug 5, 2026 | Jun 30, 2026 | 0.2692 | 0.34 | +0.07 | +26.30% |
| May 6, 2026 | Mar 31, 2026 | 0.3456 | 0.40 | +0.05 | +15.74% |
| Feb 24, 2026 | Dec 31, 2025 | 0.11 | 0.13 | +0.02 | +18.18% |
| Nov 5, 2025 | Sep 30, 2025 | 0.13 | 0.19 | +0.06 | +46.15% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 20, 2026 | Jefferies | down | Buy | Hold |
| Oct 16, 2026 | Goldman Sachs | init | — | Buy |
| Aug 6, 2026 | UBS | main | Buy | Buy |
| Aug 6, 2026 | Keybanc | main | Overweight | Overweight |
| Jul 22, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- elanco.com
News
Elanco Animal Health Q3 Earnings Call Highlights
Elanco Animal Health Sees Strong Momentum Heading Into 2027
Elanco Animal Health Q3 2026 Earnings Call Transcript
Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Surpass Estimates Elanco Animal Health Sees Q4 Adj EPS $0.16-$0.19 vs $0.18 Est; Sees Sales $1.190B-$1.215B vs $1.193B Est
Elanco Animal Health Raises FY2026 Adj EPS Guidance from $1.10-$1.16 to $1.17-$1.20 vs $1.13 Est; Raises FY2026 Sales Guidance from $5.090B-$5.140B to $5.155B-$5.180B vs $5.132B Est
Elanco Animal Health Q3 Adj. EPS $0.27 Beats $0.20 Estimate, Sales $1.265B Beat $1.208B Estimate
Elanco Animal Health Reports Third Quarter 2026 Results
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test
Your note
Sign in to keep a note on ELAN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BETTINGTON TIMOTHY J | Officer | Sale | Oct 14, 2026 | 138,911 |
| CABRAL RAMIRO MARTIN | Officer | Stock Award(Grant) | Feb 26, 2026 | 290,366 |
| DE BRABANDER ELLEN | Officer | Stock Award(Grant) | Mar 31, 2026 | 280,821 |
| HOOVER R DAVID | Director | Stock Award(Grant) | May 20, 2026 | 277,371 |
| KINARD DAVID S | Officer | Stock Award(Grant) | Feb 26, 2026 | 217,697 |
| KURZIUS LAWRENCE ERIK | Director | Purchase | Aug 19, 2026 | 188,647 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Inc. | 13.49% | 67,397,025 | 1.73B | Jun 29, 2026 |
| FMR, LLC | 11.40% | 56,948,819 | 1.47B | Jun 29, 2026 |
| Blackrock Inc. | 9.78% | 48,849,973 | 1.26B | Jun 29, 2026 |
| Primecap Management Company | 9.10% | 45,445,012 | 1.17B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.75% | 28,750,719 | 739.76M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.02% | 25,069,982 | 645.05M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 8.63% | 43,107,500 | 1.11B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 17,796,673 | 457.91M | Sep 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 3.55% | 17,751,139 | 456.74M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 15,872,148 | 408.39M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.40% | 11,974,227 | 308.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 11,448,318 | 294.57M | Jun 29, 2026 |
